Examining Targeted Therapies for Hodgkin Lymphoma in the Post-Transplant Setting: Reason for Optimism

Meeting Overview

We are pleased to invite you to our satellite symposium, Examining Targeted Therapies for Hodgkin Lymphoma in the Post-Transplant Setting: Reason for Optimism, to be held on February 18, 2016 at the 2016 BMT Tandem Meetings in Honolulu, Hawaii.


Welcome and introduction
John W. Sweetenham, MD, FRCP, FACP
12.30 PM Clinical case #1―A newly-diagnosed patient with high-risk Hodgkin lymphoma (HL)
Stephen Ansell, MD, PhD
12.35 PM Defining high risk for relapse following autologous stem cell transplant (ASCT): Who are they?
Stephen Ansell, MD, PhD
12.50 PM Questions from the audience/faculty discussion
12.55 PM Clinical case #2―A patient with relapsed/refractory HL
John W. Sweetenham, MD, FRCP, FACP
1.00 PM Targeted therapy for HL following ASCT: Decisions that can make a difference
John W. Sweetenham, MD, FRCP, FACP
1.20 PM Questions from the audience/faculty discussion
1.25 PM Conclusions and prIME Points
Stephen Ansell, MD, PhD
1.30 PM Adjourn


  • Stephen Ansell, MD, PhDMayo Clinic
    Rochester, Minnesota
  • John W. Sweetenham, MD, FRCP, FACPHuntsman Cancer Institute
    University of Utah Health Care
    Salt Lake City, Utah, United States

Target Audience

This educational activity is specifically designed to meet the needs of hematologists, oncologists, bone marrow transplant (BMT) specialists and other healthcare professionals involved in the treatment of patients with HL.

Learning Objectives

  • Define patients with high-risk HL due to known risk factors both at the time of initial diagnosis, as well as the relapsed/refractory setting
  • Describe the role of interim fluorodeoxyglucose-positron emission tomography (FDG-PET) to assess responsiveness of the disease to therapy
  • Consider which patients may be candidates for targeted consolidation therapy post-autologous stem cell transplant (ASCT)
  • Discuss the targeted therapies currently approved or in clinical trials for post-transplant therapy


Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Register Now

Date and Location

Thursday, February 18, 2016
12.30 PM – 1.30 PM

Hawaii Convention Center
1801 Kalakaua Ave
Honolulu, Hawaii 96815


This activity is provided by the Medical College of Wisconsin and organized by prIME Oncology.

Medical College of Wisconsin

Continuing Education

The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


The Medical College of Wisconsin designates this live activity for a maximum of 1 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This educational activity is supported by a grant from Seattle Genetics.